Advertisement

Topics

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

2014-08-27 03:54:12 | BioPortfolio

Summary

The purpose of this trial is to study:

- Effects of arzoxifene on bone fractures and bone mass.

- Effects of arzoxifene on getting breast cancer.

- Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke.

- Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health.

- Effects of arzoxifene on the uterus.

- The safety of arzoxifene and any side effects.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Osteoporosis, Postmenopausal

Intervention

Arzoxifene, Placebo

Location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559)
Elk Grove
Illinois
United States
60007

Status

Completed

Source

Eli Lilly and Company

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:54:12-0400

Clinical Trials [830 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).

Effects of Arzoxifene on Bone Mass and the Uterus

The purposes of this study are to determine: - The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. - The effects ...

A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.

MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

Study of Investigational Drug in Osteoporosis

The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis.

PubMed Articles [1564 Associated PubMed Articles listed on BioPortfolio]

Prevalence of osteoporosis and osteopenia in patients occupationally active.

Osteoporosis is a public health problem worldwide, affecting more than 200 million people. It is estimated that 30 to 50% of postmenopausal women suffer from it. According to the International Osteopo...

A novel anti-osteoporotic agent that protects against postmenopausal bone loss by regulating bone formation and bone resorption.

Postmenopausal osteoporosis is a bone metabolism disease that is caused by an imbalance between bone-resorbing osteoclast and bone-forming osteoblast actions. Herein, we describe the role of troxeruti...

Methylation of bone SOST impairs SP7, RUNX2, and ER transactivation in patients with postmenopausal osteoporosis.

Sclerostin (SOST), a glycoprotein predominantly secreted by bone tissue osteocytes, is an important regulator of bone formation, and loss of SOST results in Van Buchem disease. DNA methylation regulat...

Factors related with osteoporosis treatment in postmenopausal women.

Although fractures had high mortality and morbidity, many studies proved that fracture risk might be decreased by pharmacological therapy, although a low treatment adherence rate is observed. The aim ...

Long-term effects of functional impairment on fracture risk and mortality in postmenopausal women.

Our findings imply that simple functional tests can predict both hip fracture risk and excess mortality in postmenopausal women. Since the tests characterize general functional capacity (one-legged st...

Medical and Biotech [MESH] Definitions

Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

More From BioPortfolio on "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Searches Linking to this Trial